CytRx (NASDAQ:CYTR) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of CytRx (NASDAQ:CYTRGet Rating) in a report released on Tuesday. The brokerage set a “hold” rating on the stock.

Shares of CYTR opened at $0.13 on Tuesday. The firm has a market cap of $5.57 million, a P/E ratio of -0.85 and a beta of 1.89. CytRx has a fifty-two week low of $0.13 and a fifty-two week high of $4.70. The firm has a 50-day simple moving average of $0.37.

About CytRx (Get Rating)

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor.

Recommended Stories

Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.